TAG:
clinical laboratory test
How Local Path Groups Can Keep Patient Access
By Robert Michel | From the Volume XI No.13 – September 20, 2004 Issue
CEO SUMMARY: For pathology groups operating their own histology and cytology labs, a growing problem is access to patients covered by exclusive managed care contracts. In the Northeast, several persistent pathology group practices are using some effective business strategies to fight this…
Florida Issues State RFP For Sole Medicaid Lab
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: If competitive bidding for Medicare business is something universally viewed as bad by the laboratory industry, then the lab services RFP issued by Florida’s Medicaid program must be considered a serious threat to the status quo. Further, the fact that Medicaid officials in…
Labs In United Kingdom Study U.S., Canadian Labs
By Robert Michel | From the Volume X No. 2 – February 10, 2003 Issue
CEO SUMMARY: It was a groundbreaking first for both sides of the Atlantic. Senior pathologists and laboratory directors in the United Kingdom spent two days learning from their North American counterparts about the challenges and difficulties in laboratory consolidation and regionalizatio…
Docs’ In-Office Testing Showing Mixed Trends
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
CEO SUMMARY: Despite the burdens of CLIA certification and reduced reimbursement for lab tests, many medical practice experts are advising doctors to expand in-office testing. However, diagnostic technologies for near-patient testing are still not robust enough to support this trend. Earl…
Reactions To FL Court’s Ruling On Clin Path Fees
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: Reimbursement for clinical pathology professional services is under attack in a variety of ways throughout the United States. Recently a Florida Court of Appeal added a new court ruling to the growing body of legal decisions on this topic. Careful study of the ruling shows th…
Two Blood Brothers Use “Free Testing” Strategy
By Robert Michel | From the Volume IX No. 12 – August 26, 2002 Issue
CEO SUMMARY: It’s a business strategy that Quest Diagnostics Incorporated and Laboratory Corporation of America use in selected areas where they have lost exclusive managed care contracts to regional lab competitors. In order to retain access to a physician’s fee-for-service testing b…
CPI Lab Fee Adjustment Threatened by New Bill
By Robert Michel | From the Volume IX No. 8 – June 3, 2002 Issue
CEO SUMMARY: Once again, the laboratory testing industry has been singled out as a healthcare “whipping boy” by Congressional aides. In working to develop the next federal budget, legislators again propose to deny annual CPI price updates for laboratory tests. This won’t be anything…
California Lab Regulators Are A Tough Bunch
By Robert Michel | From the Volume IX No. 7 – May 13, 2002 Issue
CEO SUMMARY: By law, government regulators cannot comment publicly about the actions they take against the companies they regulate. That’s why the lab industry never learned that other public lab companies operating in California, following inspections by state authorities, were judged …
State, Federal Regulators Target Specialty Labs
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Specialty Laboratories, Inc. has earned the dubious honor of being the first-ever publicly-traded laboratory to have its CLIA-88 license revoked by federal regulators, terminating its right to payment for services covered by Medicare and Medicaid. The revocation is slated to …
Quest Pays $1.1 Billion To Acquire Unilab Corp.
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Quest Diagnostics Incorporated is showing its muscle. The dust had hardly settled on its $500 million acquisition of American Medical Laboratories when the lab industry’s behemoth announced that it would pay $1.1 billion to buy Unilab, by far the largest lab testing company…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized